Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic? is a research paper published in Frontiers in Oncology (2020). On theSindex it has a DataRank of 0.470. It has been cited 22 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.470
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NCI NIH HHS
Grant: R37 CA218707
National Institutes of Health
Grant: 5R37CA218707-07
Unmet needs for specific subsets of EGFR mutated lung cancer
National Institutes of Health
FWCI
1.22
Citation Percentile
0.8%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals